Perspectives
AI in Drug Discovery
Over the past 50 years, drug discovery has focused largely on high-throughput screening for known disease-associated targets. This makes drug discovery a long, expensive and largely unsuccessful process.
People
Antonio Russo
Head of Analytics & Cognitive
Innovation Leader and Partner
Antonio leads Deloitte's Analytics & Cognitive Advisory in Switzerland and is responsible for Innovation within Deloitte Switzerland’s Executive team. His team helps clients leverage the power of artificial intelligence and data to deliver more customer-centric and innovative products and services that catalyse growth and efficiencies.
He has over 20 years of experience in advising companies in large-scale global transformations, leveraging new delivery models (GBS/SSC, outsourcing) and innovative technologies (e.g. robotics, machine learning, natural language processing/generation). He helps global private sector and financial services organisations review and implement new strategies for business support functions, and deploy more effective and efficient services and governance models. Prior to joining Deloitte in April 2013, he held various sales and consulting leadership positions across Europe and was CEO of a start-up company developing brand protection technologies.
Related content
Perspectives
Intelligent biopharma
The biopharmaceutical sector is facing digital disruption from multiple sources, the chief among them being artificial intelligence (AI) and cloud. Deloitte predicts that in 2019/2020, all industries will accelerate their use of cloud-based AI software and services, including biopharma companies.
Perspectives
Cognitive Advantage for the Insurance and Health Insurance industry in Switzerland
Intelligent Automation (IA) or Robotic Cognitive Automation (RCA) is changing the way business is done in every sector of the economy.